Skip to main content
OpenTrials
Completed

NCT Number: NCT00685815

Intravenous Iron Metabolism in Restless Legs Syndrome

Double-blind, placebo-controlled, entitled: "Intravenous Iron Metabolism in Restless Legs Syndrome

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

The Johns Hopkins Bayview Medical Center

Baltimore, Maryland, 21224, United States

About this study

To determine the effects of high-dose infusions of iron on Restless Legs Syndrome (RLS) symptoms and brain concentrations of iron.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of Restless Legs Syndrome (RLS).
  • Presence of increased periodic leg movements of sleep (PLMS) before receiving treatment.
  • Patient sleep times are between 9pm and 9am.
  • Patient's RLS symptoms would occur daily if you were not on medication.

Exclusion criteria

  • RLS secondary to other medical disorders as determined by history and physical/neurological examination.
  • On a treatment (e.g., psychiatric medication) that might significantly alter RLS symptoms or study results and who cannot discontinue medication for the extended period of the study.
  • History of multiple adverse drug reactions or specifically an allergy to IV iron.
  • Currently experiencing a serious medical condition (chronic organ failure, active inflammation or infection, congestive heart failure, etc.) that might alter iron metabolism, would place them at risk, or interfere with study participation.
  • An magnetic resonance imaging (MRI) is not possible because of medical reasons (Pacemaker; loose iron in the tissue) or concern about severe claustrophobia.
  • Any condition that is likely to increase iron loss (chronic bleeding, excluding menstruation; medically necessary phlebotomy) or consumption (pregnancy).
  • Serum ferritin >300mg/L or percent iron saturation >50%. This is to exclude subjects with probable hemochromatosis.
  • Significant medical (e.g., inflammatory bowel syndrome; bowel dysmotility syndromes) or surgical (e.g., gastrojejunal bypass, colectomy) GI tract problems; and active chronic inflammatory processes (e.g., active hepatitis, rheumatoid arthritis, systemic lupus erythematosus). This is to exclude conditions which will potentially alter iron metabolism.

Treatment and study plan

Ferric Carboxymaltose (FCM)

Drug

500mg FCM in 250cc normal saline (NS) IV over one hour, once on Day 3, once on Day 4

Other names: Injectafer

Placebo

Drug

250cc normal saline (NS) IV over one hour, once on Day 3, once on Day 4

Primary outcomes

  1. Duration Off Treatment

    Time frame: 2 weeks, 4 weeks, and 52 weeks

    Number of weeks that patients were able to remain off treatment for RLS

Sponsors and collaborators

Lead sponsor

American Regent, Inc.

Industry

Collaborators

  • National Institute on Aging (NIA)

Registry information

Acronym: RLS

Important dates

Study start
2006
Primary completion
2010
Study completion
2012
First posted
May 28, 2008
Registry last updated
May 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.